BioCryst Pharma (BCRX) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.32), $0.02 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $65.2 million versus the consensus estimate of $63.33 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioCryst Pharma (BCRX) Tops Q3 EPS by 5c ; Offers Guidance
- Netflix gains after Ackman endorsement and AI feature launch
- Qualcomm stock climbs after SpaceX 5G network deal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
